Kardiolytics Inc.

Kardiolytics Inc. is a leading innovator in medical equipment manufacturing, specializing in cutting-edge solutions for cardiac health. Kardiolytics Inc. has developed the Virtual Cardiac Stress Test (VCAST), a patented, AI-based medical system that provides non-invasive, clinical quantitative, and qualitative analysis of CT-scan data. This technology is designed to assess the hemodynamic significance of coronary artery atherosclerotic stenosis, offering rapid and inexpensive results.

The Kardiolytics cardiac test delivers personalized, color-coded, 3D modeling of coronary arteries, combined with detailed, functional diagnostic information regarding blood flow. Computed quantities of blood, pressure, and velocity assist physicians in completing diagnoses and designing effective treatment plans for coronary artery disease. All data required for VCAST are derived from widely available and inexpensive CT-scan imaging, making it independent of specific imaging equipment, protocols, and vendors. Kardiolytics Inc. is headquartered in Chicago, US.

Kardiolytics Inc. is dedicated to transforming cardiac diagnostics with innovative technology. The Kardiolytics solution offers insights typically obtained only through invasive procedures, now available non-invasively and remotely. We invite the manager of Kardiolytics Inc. to create a customized and exclusive company showcase and product listing on our platform, enhancing their market presence and commercial development.